18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients — Stella

Recruiting

Back to Tuberculosis, Pulmonary trials

Trial locations(1 site)

United States

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Key details

Sponsor

Children's Hospital Medical Center, Cincinnati

Collaborators

National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment target

~30 participants

Started

March 2026

Primary completion

July 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov